Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 110

Related Citations for PubMed (Select 22864303)

1.

Dose findings of antofloxacin hydrochloride for treating bacterial infections in an early clinical trial using PK-PD parameters in healthy volunteers.

Li YF, Wang K, Yin F, He YC, Huang JH, Zheng QS.

Acta Pharmacol Sin. 2012 Nov;33(11):1424-30. doi: 10.1038/aps.2012.68. Epub 2012 Aug 6.

2.

Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection.

Xiao XM, Xiao YH.

Acta Pharmacol Sin. 2008 Oct;29(10):1253-60. doi: 10.1111/j.1745-7254.2008.00872.x.

3.

Pharmacokinetics of antofloxacin hydrochloride, a new fluoroquinolone antibiotic, after single oral dose administration in Chinese healthy male volunteers.

Xiao Y, Lu Y, Kang Z, Zhang M, Liu Y, Zhang M, Li T.

Biopharm Drug Dispos. 2008 Apr;29(3):167-72. doi: 10.1002/bdd.600.

PMID:
18240275
4.

Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint.

Drusano GL, Preston SL, Hardalo C, Hare R, Banfield C, Andes D, Vesga O, Craig WA.

Antimicrob Agents Chemother. 2001 Jan;45(1):13-22.

5.
6.

Population pharmacokinetics of oral levofloxacin 500 mg once-daily dosage in community-acquired lower respiratory tract infections: results of a prospective multicenter study in China.

Zhang J, Xu JF, Liu YB, Xiao ZK, Huang JA, Si B, Sun SH, Xia QM, Wu XJ, Cao GY, Shi YG, Zhang YY.

J Infect Chemother. 2009 Oct;15(5):293-300. doi: 10.1007/s10156-009-0714-8. Epub 2009 Oct 24.

PMID:
19856067
7.

Population pharmacokinetic and pharmacodynamic modeling of norvancomycin.

Zhang J, Zhang Y, Shi Y, Rui J, Yu J, Cao G, Wu J.

Eur J Clin Microbiol Infect Dis. 2008 Apr;27(4):275-84. doi: 10.1007/s10096-007-0435-9. Epub 2008 Jan 9.

PMID:
18188617
8.
9.

Tolerability and pharmacokinetics of antofloxacin hydrochloride after multiple oral dose administration in healthy Chinese male volunteers.

Xiao Y, Lu Y, Kang Z, Hou F, Wang S, Li T, Liu Y, Xia Y.

Int J Clin Pharmacol Ther. 2008 Apr;46(4):172-9.

PMID:
18397690
10.

Pharmacodynamics of the new des-f(6)-quinolone garenoxacin in a murine thigh infection model.

Andes D, Craig WA.

Antimicrob Agents Chemother. 2003 Dec;47(12):3935-41.

11.

Pharmacokinetic study of single and multiple oral dose administration of antofloxacin hydrochloride in healthy male volunteers.

Lü Y, Kang ZS, Zhu Y, Zhang M, Liu Y, Zhang M, Li TY, Xiao YH.

Chin Med J (Engl). 2011 Jan;124(2):242-5.

PMID:
21362374
12.

Vancomycin dosing assessment in intensive care unit patients based on a population pharmacokinetic/pharmacodynamic simulation.

Revilla N, Martín-Suárez A, Pérez MP, González FM, Fernández de Gatta Mdel M.

Br J Clin Pharmacol. 2010 Aug;70(2):201-12. doi: 10.1111/j.1365-2125.2010.03679.x.

13.

Integration of pharmacokinetic and pharmacodynamic indices of marbofloxacin in turkeys.

Haritova AM, Rusenova NV, Parvanov PR, Lashev LD, Fink-Gremmels J.

Antimicrob Agents Chemother. 2006 Nov;50(11):3779-85. Epub 2006 Aug 28.

14.

Pharmacokinetics of antofloxacin hydrochloride in healthy male subjects after multiple intravenous dose administration.

Wang J, Xiao Y, Lu Y, Kang Z, Zhang M, Liu Y, Liang J, Zhang M, Li T.

Xenobiotica. 2011 Jul;41(7):561-6. doi: 10.3109/00498254.2011.565820. Epub 2011 Mar 29.

PMID:
21446836
15.

Pharmacokinetics of antofloxacin hydrochloride, a novel fluoroquinolone, after single-dose intravenous administration in healthy Chinese male volunteers.

Wang J, Xiao Y, Lu Y, Kang Z, Zhang M, Liu Y, Liang J, Zhang M, Li T.

Xenobiotica. 2010 May;40(5):344-9. doi: 10.3109/00498251003649798.

PMID:
20230254
16.

Intrapulmonary pharmacokinetics and pharmacodynamics of high-dose levofloxacin in healthy volunteer subjects.

Conte JE Jr, Golden JA, McIver M, Zurlinden E.

Int J Antimicrob Agents. 2006 Aug;28(2):114-21. Epub 2006 Jul 11.

PMID:
16837169
17.

Safety and clinical pharmacokinetics of nemonoxacin, a novel non-fluorinated quinolone, in healthy Chinese volunteers following single and multiple oral doses.

Guo B, Wu X, Zhang Y, Shi Y, Yu J, Cao G, Zhang J.

Clin Drug Investig. 2012 Jul 1;32(7):475-86. doi: 10.2165/11632780-000000000-00000.

PMID:
22650326
18.

Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials.

Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, Reichl V, Natarajan J, Corrado M.

JAMA. 1998 Jan 14;279(2):125-9.

PMID:
9440662
19.
20.

Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline.

Bhavnani SM, Rubino CM, Hammel JP, Forrest A, Dartois N, Cooper CA, Korth-Bradley J, Ambrose PG.

Antimicrob Agents Chemother. 2012 Feb;56(2):1065-72. doi: 10.1128/AAC.01615-10. Epub 2011 Dec 5.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk